← Leaderboards
Maria Sirenko
Sloan-Kettering Inst Can Research
$91,556
Attributed
$91,556
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $46K · FY2020–21$50K$37.5K$25K$12.5K$0
'20
'21
Funding mix
By agency
NIH$91,556 · 1
By mechanism
F31$91,556 · 1
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Ross L Levine$31,715,816
- Omar Abdel-Wahab$18,758,829
- Timothy An-Thy Chan$21,076,830
- Eirini Papapetrou$13,419,805
- David B. Solit$21,393,031
Others in their field
Other Emerging Leaders on “Acute Myelocytic Leukemia”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$158,144,386
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,430,568
- Crystal Mackall · Children'S Hosp Of Philadelphia$6,450,142
- Christopher A Miller · Washington University$5,424,298
- Eric Padron · H. Lee Moffitt Cancer Ctr & Res Inst$5,329,699
- Kelly Diringer Getz · University Of Pennsylvania$4,068,250
Research focus
Acute Myelocytic LeukemiaAcuteAutomobile DrivingBiologicalAllelic ImbalanceBloodCancer BiologyCancer GenomicsCancer InitiationCancer PatientCellsBiologyChemotherapyChemotherapy And/Or RadiationClinical CareClinically RelevantClinical TrialsCytotoxic ChemotherapyDetectionDiagnosisDisease ProgressionDriver MutationEarly DiagnosisEarly Intervention
Grant awards (2)
Defining the biological consequences of somatic mutations in high risk AML using integrative single cell approaches$46,036
F31 · FY2021 · CA · contact PI
Defining the biological consequences of somatic mutations in high risk AML using integrative single cell approaches$45,520
F31 · FY2020 · CA · contact PI